Analysts See $0.02 EPS for IAMGOLD (IMG); Eleven Biotherapeutics (EBIO) Sentiment Is 2.25

April 17, 2018 - By Marguerite Chambers

IAMGOLD Corporation (TSE:IMG) Logo

Eleven Biotherapeutics (EBIO) investors sentiment increased to 2.25 in Q4 2017. It’s up 1.70, from 0.55 in 2017Q3. The ratio is positive, as 9 institutional investors opened new or increased equity positions, while 4 cut down and sold stakes in Eleven Biotherapeutics. The institutional investors in our database now possess: 1.80 million shares, up from 1.21 million shares in 2017Q3. Also, the number of institutional investors holding Eleven Biotherapeutics in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 2 Increased: 5 New Position: 4.

Analysts expect IAMGOLD Corporation (TSE:IMG) to report $0.02 EPS on May, 8 after the close.They anticipate $0.01 EPS change or 100.00% from last quarter’s $0.01 EPS. T_IMG’s profit would be $9.33 million giving it 87.63 P/E if the $0.02 EPS is correct. After having $-0.04 EPS previously, IAMGOLD Corporation’s analysts see -150.00% EPS growth. The stock decreased 0.28% or $0.02 during the last trading session, reaching $7.01. About 484,127 shares traded. IAMGOLD Corporation (TSE:IMG) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 7 analysts covering Iamgold Corp (TSE:IMG), 3 have Buy rating, 3 Sell and 1 Hold. Therefore 43% are positive. Iamgold Corp had 27 analyst reports since August 6, 2015 according to SRatingsIntel. Canaccord Genuity downgraded it to “Hold” rating and $9.50 target in Friday, September 29 report. The rating was downgraded by Mackie on Friday, February 19 to “Sell”. The stock of IAMGOLD Corporation (TSE:IMG) earned “Market Perform” rating by BMO Capital Markets on Wednesday, June 7. On Friday, February 24 the stock rating was maintained by TD Securities with “Buy”. TD Securities upgraded the stock to “Buy” rating in Tuesday, November 8 report. The firm earned “Sector Perform” rating on Tuesday, November 8 by Scotia Capital. The firm has “Underperform” rating by Scotia Capital given on Monday, January 23. Scotia Capital maintained it with “Sector Perform” rating and $5.75 target in Tuesday, December 20 report. The stock of IAMGOLD Corporation (TSE:IMG) earned “Underperform” rating by Scotia Capital on Friday, February 24. The company was maintained on Tuesday, January 17 by Scotia Capital.

IAMGOLD Corporation explores for, develops, and operates gold mining properties in North and South America, and West Africa. The company has market cap of $3.27 billion. It also explores for copper and silver. It has a 6.55 P/E ratio. The firm owns interest in the Rosebel gold mine located in north eastern Suriname, South America; Essakane gold mine in north-eastern Burkina Faso, West Africa; Westwood gold mine in southwestern Qu??bec, Canada; and Sadiola, as well as Yatela gold mines situated in southwest Mali, West Africa.

Virtu Financial Llc holds 0.02% of its portfolio in Eleven Biotherapeutics, Inc. for 427,048 shares. Bank Of New York Mellon Corp owns 44,849 shares or 0% of their US portfolio. Moreover, Blackrock Inc. has 0% invested in the company for 445,463 shares. The Texas-based Bridgeway Capital Management Inc has invested 0% in the stock. Citadel Advisors Llc, a Illinois-based fund reported 15,372 shares.

The stock decreased 3.73% or $0.059 during the last trading session, reaching $1.521. About 1.03 million shares traded. Eleven Biotherapeutics, Inc. (EBIO) has declined 52.78% since April 17, 2017 and is downtrending. It has underperformed by 64.33% the S&P500.

Analysts await Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) to report earnings on May, 3. They expect $-0.13 earnings per share, up 48.00% or $0.12 from last year’s $-0.25 per share. After $-0.22 actual earnings per share reported by Eleven Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts -40.91% EPS growth.

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics . The company has market cap of $65.56 million. It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. It currently has negative earnings. The companyÂ’s lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck.

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.